Literature DB >> 28740609

Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.

Chad M Kormos1, Pauline W Ondachi1, Scott P Runyon1, James B Thomas1, S Wayne Mascarella1, Ann M Decker1, Hernán A Navarro1, F Ivy Carroll1.   

Abstract

Potent and selective κ opioid receptor antagonists have been derived from the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. In order to determine if the 3-hydroxyphenyl and/or the piperidine amino groups are required for obtaining the pure opioid antagonists, (3R)-7-hydroxy-N-[(1S)-2-methyl-1-(piperidine-1-ylmethyl)propyl]-1,2,3,4-tetrahydroiosquinoline-3-carboxamide (1), which does not have a 4-(3-hydroxyphenyl) group, and (3R)-N-(1R)-1-(cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (2), which does not have a 4-hydroxylphenyl or a piperidine amino group, were synthesized and evaluated for their [35S]GTPγS binding properties at the μ, δ, and κ opioid receptors. Surprisingly compound 1 remained a pure opioid antagonist with a Ke = 6.80 nM at the κ opioid receptor and is 21- and 441-fold selective for the κ receptor relative to the μ and δ opioid receptors, respectively. Even more unexpected and novel is the finding that 2 has a Ke = 0.14 nM at κ and is 1730- and 4570-fold selective for κ relative to the μ and δ opioid receptors, respectively.

Entities:  

Keywords:  JDTic; Opioid receptor; functional assays; kappa opioid receptor antagonists; tetrahydroisoquinoline

Year:  2017        PMID: 28740609      PMCID: PMC5512122          DOI: 10.1021/acsmedchemlett.7b00115

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine.

Authors:  Ajay N Jain
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

2.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

Authors:  Travis T Wager; Xinjun Hou; Patrick R Verhoest; Anabella Villalobos
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

3.  Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.

Authors:  Scott G Summerfield; Kevin Read; David J Begley; Tanja Obradovic; Ismael J Hidalgo; Sara Coggon; Ann V Lewis; Rod A Porter; Phil Jeffrey
Journal:  J Pharmacol Exp Ther       Date:  2007-04-03       Impact factor: 4.030

4.  The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats.

Authors:  Gerald A Deehan; David L McKinzie; F Ivy Carroll; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

Review 5.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.

Authors:  K J Jackson; Frank Ivy Carroll; S S Negus; M I Damaj
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

7.  Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Authors:  Allison T Knoll; Edward G Meloni; James B Thomas; F Ivy Carroll; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2007-09-06       Impact factor: 4.030

8.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

9.  Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.

Authors:  F Ivy Carroll; Moses G Gichinga; Chad M Kormos; Rangan Maitra; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro
Journal:  Bioorg Med Chem       Date:  2015-08-25       Impact factor: 3.641

10.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery.

Authors:  Arup K Ghose; Torsten Herbertz; Robert L Hudkins; Bruce D Dorsey; John P Mallamo
Journal:  ACS Chem Neurosci       Date:  2011-11-02       Impact factor: 4.418

View more
  2 in total

1.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Authors:  Pauline W Ondachi; Chad M Kormos; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

2.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Authors:  Chad M Kormos; Pauline W Ondachi; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.